 Home > Medical News > Medicines Company News > Cinda ophthalmic drug IBI302 Phase II clinical completed the first patient administration

Cinda ophthalmic drug IBI302 Phase II clinical completed the first patient administration

 Last Update: 2021-05-10
 Source: Internet
 Author: User

Tags

treatment cystic fibrosis

anti glycation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 29, Innovent announced that its first phase II clinical study of the world's first ophthalmic anti-VEGF-complement dual target drug (R&D code: IBI302) has completed the first patient administration.

This study is a randomized, double-blind, multi-center, randomized, double-blind, multi-centered study in subjects with active subfoveal or parafoveal choroidal neovascularization secondary to neovascular age-related macular degeneration (nAMD) An activity-controlled phase II clinical study.

Anti-VEGF drugs have become the standard treatment for nAMD: Based on the inhibition of VEGF, the vision and ocular anatomy of most patients can be significantly improved.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.